DADC
ECYT

D.A. Davidson & Co’s Endocyte, Inc. Common Stock ECYT Stock Holding History

D.A. Davidson & Co’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-257
Closed -$2K – 2250
2013
Q4 		$2K Buy
+257
New +$2.84K ﹤0.01% 1988

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

D.A. Davidson & Co's ECYT Position: Q1 2014 in Review

D.A. Davidson & Co sold out of Endocyte, Inc. Common Stock (ECYT) in Q1 2014, closing a stake of 257 shares — an estimated $2K sold.

D.A. Davidson & Co first reported a position in ECYT in Q4 2013 and held it in 1 quarter. The position peaked at $2K in Q4 2013. 121 funds tracked by Wall St. Rank hold ECYT as of Q1 2014.

  • D.A. Davidson & Co reported no remaining Endocyte, Inc. Common Stock position as of Q1 2014 after selling out during the quarter.
  • D.A. Davidson & Co sold 257 Endocyte, Inc. Common Stock shares in Q1 2014, an estimated $2K.
  • D.A. Davidson & Co first reported a position in Endocyte, Inc. Common Stock in Q4 2013 and held it in 1 quarter.
  • D.A. Davidson & Co's Endocyte, Inc. Common Stock position peaked at $2K in Q4 2013.
  • 121 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q1 2014.

Based on D.A. Davidson & Co's 13F filing for Q1 2014, filed 5 May 2014.